Finally, clinical studies testing etrolizumab—a monoclonal antibody blocking beta 7 integrin, the heterodimeric partner of CD103—in IBD are currently underway providing putatively additional indirect evidence that CD103 may represent a novel promising therapeutic target candidate in the future [29]. This evidence concerns the gene ITGB7 and inflammatory bowel disease.